Document is current

Article History

Received: 17 August 2024

Accepted: 19 August 2024

First Online: 28 August 2024

Declarations

:

: SC declares honoraria from the British Association of Psychopharmacology, Canadian ADHD Resource Alliance, Association for Child and Adolescent Mental Health, and Medice. He has served on the advisory board of the Association for Child and Adolescent Mental Health (ACAMH). He has served as deputy editor of Evidence Based Mental Health (now BMJ Mental Health), associate editor of Child and Adolescent Mental Health, and on the editorial board of the Journal of Child Psychology and Psychiatry. DC declares grants from the National Health and Medical Research Council and the Medical Research and Futures Fund; royalties from Oxford University Press and Cambridge University Press; honoraria from Takeda, Medice, Servier, and Novartis; support for attending meetings or travel from the European College of Neuropsychopharmacology; and is the Director of the Australian ADHA Professionals Association and the European Network for Hyperkinetic Disorders. JMF declares no competing conflicts of interest GWM declares consulting fees, honoraria, and participation data safety monitoring board for Corium, Supernus, Ironshore, Tris, Akilly, Lumos Lab, and Revibe; and stock in Revibe. LAR declares grants from the National Council for Scientific and Technological Development and the United States National Institutes of Health (R01MH120482); royalties from ARTMED and Oxford Press; consulting fees from Adium, Aspen, Medice, Novartis/Sandoz, and Shire/Takeda; honoraria from Abdi Ibrahim, Abbott, Aché, Adium, Apsen, Bial, Medice, Novartis/Sandoz, Pfizer/Upjohn/Viatris, and Shire/Takeda; support for attending meetings from Stavros Niarchos Foundation; participation data safety monitoring board for Adium, Apsen, Medice, Novartis/Sandoz, and Shire/Takeda; and is the President for the International Association of Child and Adolescent Psychiatry and Allied Disciplines.RPT has received research funding from Piton Therapeutics, AACAP, the Jerome Lejeune Foundation, the Massachusetts General Hospital Louis V. Gerstner III Research Scholar Award, the Mass General Neuroscience Transformative Scholar Award, the Williams Syndrome Association, and the NIMH; royalties from Oxford University Press and Springer; and is on the advisory board for Targeted Education for Autism Management across Medical Specialities.TEW declares grants from NIH, royalties from Ironshore, Guilford press and Cambridge University press, and consultation fees from Gavin Foundation, Bay Cove Human Services, US National Football League, US Minor/Major league Baseball, White Rhino 3D, and Massachusetts General HospitalICKW declares grants from Amgen, Janseen, GSK, Novartis, Pfizer, Bayer, Bristol-Myers Squibb, Takeda, Institute for Health Research in England, European Commission, National Health and Medical Research Council in Australia, and the Seventh Framework Programme for Research, Technological Development; consulting fees from IQVIA and WHO; payment for expert testimony from Appeal Court in Hong Kong; is a member of board for the Pharmacy and Poisons Board; is a member of the Expert Committee on Clinical Events Assessment Following COVID-19 Immunization; is a member of the advisory panel on COVID-19 vaccines of the Hong Kong Government; and is an independent non-executive director of Jacobson Medical. SVF declares grants from Otsuka, Shire/Takeda, Supernus, Arbor; royalties from Elsevier, Guilford Press Oxford University; consulting fees from Arbor, Aardvark, Aardwolf, Association for Infant Mental Health, Atentiv, Aveksham Axsome, Genomind, Ironshore, Corium, Kanjo, Johnson & Johnson/Kenvue, KemPharm/Corium, Sky Therapeutics, Medice, Noven, Rhodes, Supernus, Tris, and Vallon; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda, Supernus, Sabndoz, Otsuka, and Tris; support for attending meetings or travel from Ironshore and Supernus; US patents (US20130217702 A1); and stock or stock options in Aardvark, Aardwold, Akili, Ironshore, Sky Therapeutics, and Genomind.